HLS Therapeutics (HLS) Set to Announce Earnings on Thursday

HLS Therapeutics (TSE:HLS) will announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of C($0.19) per share for the quarter.

HLS Therapeutics (TSE:HLS) last issued its quarterly earnings results on Thursday, August 8th. The company reported C($0.25) EPS for the quarter, hitting the consensus estimate of C($0.25). HLS Therapeutics had a negative return on equity of 24.82% and a negative net margin of 40.90%. The company had revenue of C$19.87 million for the quarter, compared to the consensus estimate of C$19.25 million.

HLS Therapeutics Stock Performance

Shares of HLS traded up C$0.02 during mid-day trading on Tuesday, hitting C$3.32. The company’s stock had a trading volume of 4,547 shares, compared to its average volume of 26,324. The stock’s 50-day moving average is C$3.51 and its two-hundred day moving average is C$3.62. The firm has a market capitalization of C$105.54 million, a PE ratio of -3.27 and a beta of 1.07. The company has a debt-to-equity ratio of 100.44, a quick ratio of 1.01 and a current ratio of 2.02. HLS Therapeutics has a one year low of C$3.00 and a one year high of C$5.48.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus decreased their price target on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research report on Tuesday, August 13th.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.